Skip to content
Open access

Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity

Oct 2026 · Frontiers in Pharmacology · Vol 17 · 0 citations · 50 references
Medicine

TL;DR

Findings suggest the PRMT5/GPX4 axis as a potential therapeutic target and position RK3 as a promising candidate for chemoresistant OS.

Abstract

Background Osteosarcoma (OS), the most common primary malignant bone tumor in children and adolescents, commonly develops chemoresistance to conventional apoptosis-dependent therapies (e.g., doxorubicin) in metastatic/recurrent settings, leading to poor prognosis. Ferroptosis—an iron-dependent cell death pathway driven by lipid peroxidation—offers a promising alternative, yet clinical translation of synthetic inducers is limited by poor druggability. Purpose This study systematically investigates the antitumor efficacy of ginsenoside RK3 in OS, explores its potential involvement in the PRMT5/GPX4-ferroptosis axis, and evaluates its potential as a doxorubicin chemosensitizer. Methods Antitumor effects of RK3 were assessed in MG63/U2OS cells and OS xenografts. Mechanisms were explored through bioinformatics, molecular docking, co-immunoprecipitation, and ubiquitination assays. The combinatorial effects with doxorubicin (DOX) were evaluated in vitro and in vivo. Results RK3 potently suppressed OS growth and metastasis in vitro and in vivo without significant systemic toxicity. Mechanistically, molecular docking predicted that RK3 binds to PRMT5, and RK3 treatment downregulated PRMT5 expression, which was associated with enhanced FBW7–GPX4 interaction, increased GPX4 ubiquitination and proteasomal degradation, thereby promoting iron-dependent lipid peroxidation and ferroptosis. In combination with doxorubicin, RK3 markedly enhanced chemosensitivity and tumor suppression compared to monotherapy. Conclusion Ginsenoside RK3 inhibits OS potentially through the PRMT5/GPX4 axis to promote ferroptosis and enhances the sensitivity of tumors to doxorubicin, demonstrating a favorable safety profile. These findings suggest the PRMT5/GPX4 axis as a potential therapeutic target and position RK3 as a promising candidate for chemoresistant OS.

Read PDF

Similar papers

Nov 2026

JQ1 targeting BRD4 enhances cisplatin-induced pyroptosis via LDHA-mediated ROS release to potentially overcome chemoresistance in bladder cancer.

Cisplatin-based chemotherapy is a cornerstone treatment for muscle-invasive bladder cancer (MIBC), yet resistance to cisplatin and its adverse effects limit clinical efficacy. Novel strategies to sensitize tumors to cisplatin are urgently needed. As a chromatin reading protein, BRD4 can regulate gene expression and pla...

Ke Li, Ye Tan, Zhong-Bei Li et al. · 0 citations
Open access Nov 2026

Ginsenoside Compound K Inhibits Pancreatic Cancer by Induction of Canonical Pyroptosis Associated with HAPLN1 Signaling

Background: Pancreatic cancer (PC) remains one of the most lethal malignancies because of its highly immunosuppressive tumor microenvironment and profound resistance to current therapies. Increasing evidence suggests that pyroptosis, a pro-inflammatory form of programmed cell death, may provide a promising strategy for...

Jing-Ke Liu, Chao Fang, Hai-Xia Yang et al. · 0 citations
Open access Nov 2026

Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis.

BACKGROUND Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has become a mainstay treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance develops in most patients and ultimately compromises durable clinical benefit. Therefore, effective combination strategies to...

Li-Juan Wang, Xu Chen · 0 citations
Review Oct 2026

Phytochemical-drug combinations in osteosarcoma: Mechanistic vulnerabilities, evidence quality and translational challenges.

Osteosarcoma remains a major therapeutic challenge because of metastatic progression, recurrence and intrinsic or acquired resistance to conventional chemotherapy. Phytochemicals have emerged as potential complementary agents because of their ability to modulate multiple biological processes associated with osteosarcom...

N. Hashim, Hermizi Hapidin · 0 citations
Oct 2026

RASGRP2 promotes doxorubicin chemoresistance and tumor progression in osteosarcoma via the Notch1-NICD-Hes1 axis.

BACKGROUND Doxorubicin (DOX) resistance remains a major obstacle to favorable outcomes in osteosarcoma. The role of RASGRP2 in osteosarcoma chemoresistance is poorly understood. METHODS We analyzed RASGRP2 expression and prognostic value across pan-cancer datasets (TCGA, TARGET) and osteosarcoma cohorts (TARGET-OS, G...

Xue-Yi Huang, Zhen Huang, Mei-Xiu Lin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.